China Life invests up to 4.5 billion yuan in AI and chip fund

China Life Insurance, the country’s biggest life insurer, is channeling billions of yuan into funds targeting artificial intelligence and chip development. The move is part of a broader pattern of state-adjacent capital flowing into sectors Beijing considers strategically essential.

The investment of up to 4.5 billion yuan (roughly $620 million) into an AI and chip-focused fund comes as China accelerates efforts to reduce its dependence on foreign semiconductor technology.

The bigger picture behind the money

By the end of 2025, the insurer’s investments in what it categorizes as “tech self-reliance” exceeded RMB 510 billion. That figure includes an RMB 11.8 billion stake in a Shanghai integrated circuit fund launched in 2023.

In January 2026, China Life committed RMB 4 billion to a RMB 5.0515 billion partnership targeting AI, integrated circuits, and biomedicine. That vehicle, managed by China Life Capital, has a mandate to direct at least 70% of its capital toward AI applications, with particular interest in autonomous driving and embodied intelligence, the branch of AI that gives robots and physical systems the ability to perceive and interact with the real world.

Then in July 2026, the insurer followed up with a separate commitment of nearly RMB 5 billion toward an eight-year, RMB 5 billion semiconductor equity investment partnership. The fund’s target companies are those with deep expertise in chip design and related services.

The focus areas across both vehicles include intelligent chips, AI infrastructure, integrated circuits, and biomedicine. China Life is taking minority stakes rather than seeking control.

Why an insurer is betting on semiconductors

Life insurance companies sit on enormous pools of long-duration capital. Policyholders pay premiums for decades before claims come due, which means insurers need assets that match that timeline. Traditionally, that meant government bonds and real estate. But with Chinese property markets still recovering and bond yields compressed, alternative investments in growth sectors start to look more attractive.

Beijing has been nudging institutional investors in this direction, calling for more “patient capital” to support the country’s technology ambitions.

In August 2026, China Life reported revenue of RMB 434.3 billion, an 81.5% increase year-on-year. Net profit surged 228% to RMB 134.5 billion.

The geopolitical backdrop

The US and its allies have imposed increasingly stringent export controls on advanced semiconductor equipment and chips destined for China. The result has been a mobilization of domestic capital toward semiconductor self-sufficiency. Government-backed “Big Fund” vehicles have already deployed hundreds of billions of yuan into the sector. China Life’s investments represent the insurance industry’s contribution to that same national project.

The eight-year duration of the semiconductor fund reflects the long development cycles involved. Designing a competitive processor takes years, and building the manufacturing capabilities to produce it takes even longer.